NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Ionis Pharmaceuticals, Inc. IONS
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$943.7M
▲ 33.8% vs FY2024
EPS · FY25
$-2.38
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-70.8%
Net margin · FY25
-40.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 943.7M
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
USD -2.38
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-70.8%
Return on equity, FY2025
ROE
Operating margin-40.4%
Net margin-40.4%
Return on assets-11.7%
Each USD of equity lost 71 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+17.1%
+5.3%
+12.8%
+15.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.16B
Shares outstanding, FY2025
Change, 5 years+16.3%
Change, 10 years+35.7%
The share count grew 16% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.5B
total assets, end of FY2025
Total assetsUSD 3.5B
EquityUSD 489.1M
CashUSD 372.3M
Gross debtUSD 1.8B
Net debtUSD 1.4B
Current ratio3.83×
Net debt stands at 284% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.9
0.7
0.8
0.6
0.8
0.7
1.1
0.6
0.5
0.4
0.3
0.2
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
−0.4
−0.5
−0.4
−0.4
−0.0
−0.2
0.4
−0.1
0.0
−0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.4
−0.5
−0.3
−0.4
−0.0
−0.2
0.4
−0.1
0.0
−0.0
−0.1
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
0.0
0.0
−0.0
0.3
0.1
−0.3
−0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
·
Net income $B
−0.4
−0.5
−0.4
−0.3
−0.0
−0.4
0.3
0.3
0.0
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
0.2
−0.0
EPS, diluted $
−2.38
−3.04
−2.56
−1.90
−0.20
−3.18
1.90
2.07
0.15
−0.50
−0.74
−0.33
−0.55
−0.65
−0.85
−0.62
1.58
−0.19
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−70.8
−93.1
−76.3
−40.1
−3.8
−40.1
22.1
41.2
0.2
−40.2
−38.5
−12.3
−21.6
−37.0
−40.8
−22.8
51.6
·
Shares out B
0.16
0.16
0.14
0.14
0.14
0.14
0.14
0.14
0.12
0.12
0.12
0.12
0.12
0.10
0.10
0.10
0.10
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed